Inve India ▾

Curis Lifesciences share price & results

Curis Lifesciences Ltd· Healthcare

Results to
Mar 2026
Latest analysed call
Q2 FY26
Ownership as of
Mar 2026

Ahmedabad-based WHO-GMP certified pharmaceutical manufacturer making tablets, capsules, liquids and ointments via loan licensing, contract manufacturing and export.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue32.7 ₹ crore−4.8% YoYQuarterly, as filedQuarter to Mar 2026Revenue from operations as filed.
Operating margin15.7 %−4.5 pts YoYOperating profit / revenueQuarter to Mar 2026For the quarter; a change is in percentage points.
Net profit2.7 ₹ crore−32.3% YoYQuarterly, as filedQuarter to Mar 2026Profit after tax as filed.
Return on equityUnavailable−33.6 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM · period unavailableNot in the analysed materials. No older figure is substituted.
Free cash flow margin-30.08 %−26.0 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)Unavailable−22.4 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM · period unavailableNot in the analysed materials. No older figure is substituted.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Mar 2026

Guidance

What management said, and what became of it

0 of 1 judged target kept · 7 open · verdicts reflect calls analysed to Q3 FY26.

Curis Lifesciences Ltd management guidance track record on Inve: 8 targets tracked across analysed earnings calls (0 achieved, 1 missed, 7 open).

TargetOriginal wordingSaidLatest callVerdict
Tablet Capacity Utilizationachieve 80% plus tablet utilization... capacity utilization in the next 2-3 years without major capex
Call transcript, Q2 FY26 · 22 Jan 2026		Q2 FY26Q3 FY26:No specific update provided on tablet utilization percentages.
Call transcript, Q3 FY26 · no direct link		Ghosted
EBITDA Marginit will increase to 10%, it means it will be 22% in year 28 financial year.
Call transcript, Q2 FY26 · 22 Jan 2026		Q2 FY26Q3 FY26:Management now expects to hit 22% EBITDA margin in FY26 and FY27, accelerating the timeline.
Call transcript, Q3 FY26 · no direct link		Revised Up
Own Brand Marketing Revenue Contributionincrease it to 5% to 7%... by 27, March. I mean, Financial 27.
Call transcript, Q2 FY26 · 22 Jan 2026		Q2 FY26Q3 FY26:Management stated they aim to achieve 10% of total revenue from own brand in FY27-28, which aligns with the trajectory for FY27.
Call transcript, Q3 FY26 · no direct link		On Track

Source: Inve Guidance Tracker for Curis Lifesciences Ltd · to Q3 FY26

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

1 of Curis Lifesciences Ltd's 8 targets was missed. See which ones, and which are quietly gone. The 3 above are the free sample; 5 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹180 +2.01% · +₹3.55

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance +27.7% 1Y

₹100₹150₹200Nov 25Dec 25Feb 26Mar 26May 26Jun 26Aug 26Sept 26Q2 FY26 — 9 Jan 2026Q2 FY26 — 22 Jan 2026

1Y: ₹141 on 14 Nov 2025 → ₹180. High ₹230.1 (28 Sept 2026), low ₹88.8 (23 Mar 2026).

Previous close
₹176.45
Market cap
₹167 Cr
52-week range
₹88.8 – ₹230.1
Price to earnings (FY ending Mar 2026)
24.10×
Return on equity (FY ending Mar 2026)
21.70%

Overview

Symbol
NSE:CURIS
Exchange
NSE
Currency
INR

What Curis Lifesciences Ltd does

Based on the company's own presentations, annual report and earnings calls.

Curis Lifesciences operates a single WHO-GMP certified pharmaceutical manufacturing facility at Sanand GIDC-II, Ahmedabad, Gujarat, producing tablets, capsules, oral liquids, external preparations (ointments/gels/creams) and sterile ophthalmic ointments. It earns through loan licensing and contract manufacturing for domestic clients who own the brand, and through direct and merchant export of finished formulations to international markets including Yemen, Kenya, Nigeria, Ghana and the Philippines. The company is NAFDAC approved for exports to Nigeria and holds additional country-specific manufacturing/marketing registrations, and is working to shift its mix from lower-margin domestic contract manufacturing toward merchant export and own-brand sales in Africa.

Segments

  • Loan licensing
  • Contract manufacturing (domestic)
  • Direct export
  • Merchant export
Manufacturing facility
1 facility at Sanand GIDC-II, Ahmedabad, Gujarat spanning 2,827 sq. m.
Product portfolio
1,200+ products across dosage forms
Installed tablet capacity
1,380 million units/yr (43.6% utilization, as of 31/03/2025)
Installed capsule capacity
157 million units/yr (16.8% utilization, as of 31/03/2025)
Capsule filling capacity (in-house)
40,000 capsules/hour
Liquid bottle filling capacity (in-house)
7,200 bottles (100 ml)/hour
Founded 2017Headquarters Ahmedabad, Gujarat, India Company website

How the price took the results

close before → close after

Q2 FY26
+3.5%
9 Jan

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Curis Lifesciences Ltd

Free account: one company. Everything above stays public.

Write why you follow Curis Lifesciences Ltd and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Curis Lifesciences Ltd

Guides on how to read this kind of business and the numbers that matter.